2019 American Transplant Congress
Rabbit Anti-Thymocyte Globulin (rATG) Induction in Heart Transplant Recipients at High Risk for Rejection
*Purpose: To assess the safety and efficacy of rATG induction in heart transplant recipients at high risk for rejection.*Methods: This was a single-center, retrospective study…2019 American Transplant Congress
Outcomes Of Dosing Weight Selection On Rabbit Anti-thymocyte Globulin Induction Immunosuppression In High-risk, Obese Renal Transplant Recipients
*Purpose: There are limited data regarding the optimal weight-based dosing strategy for rabbit anti-thymocyte globulin (rATG) induction in renal transplantation. At our center, rATG is…2019 American Transplant Congress
Antithymocyte Globulin is Associated with Mature T Cell Phenotypes and Decreased Risk of Non-EBV Infections in Transplanted Children
*Purpose: Depletional induction therapies are known to reduce the rate of acute rejection; yet data from the US Renal Data System have shown that use…2019 American Transplant Congress
Induction Therapy in Elderly Kidney Transplant Recipients with Low Immunological Risk
*Purpose: Thymoglobulin (ATG) and Basiliximab (BSX) lead to similar rejection rates in low immunological risk patients. ATG seems to be associated with infectious and malignancy…2019 American Transplant Congress
Outcomes of Induction Therapy with Bortezomib and High-Dose Intravenous Immunoglobulin for Kidney Transplantation with Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies
Department of Urology, Ehime University, Toon, Japan
*Purpose: Preformed donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) are known to increase the risk of antibody-mediated rejection (ABMR) and graft failure. However, effective methods…2019 American Transplant Congress
Allogenic Islets Cure Diabetes Following Transplantation in Omental Pouch in a Non-Human Primate Model
*Purpose: In the current standard clinical transplant approach, islet cells are administered intravenously into the portal system where they lodge in the liver. This approach…2019 American Transplant Congress
Safety and Efficacy of Alemtuzumab Compared to Rabbit Anti-Thymocyte Globulin as Induction for Secondary Transplant after a Primary Transplant with Alemtuzumab Induction
*Purpose: Alemtuzumab and rabbit anti-thymocyte globulin (rATG) are commonly used lymphocyte depleting induction agents. Traditional thinking suggests that re-transplantation is associated with higher rejection risk,…2019 American Transplant Congress
Panel Reactive Antibody Stratification as a Guide to Induction Selection in Deceased-Donor Kidney Transplantation: Impact of Clinical Practice on Outcomes
*Purpose: We aimed to determine the outcomes associated with anti-thymocyte globulin (ATG), alemtuzumab (ALM) or interleukin-2 receptor antagonist (IL2-RA) induction in adult deceased-donor (DD) kidney…2019 American Transplant Congress
Simultaneous Pancreas and Kidney Transplant Outcomes after Induction Therapy with Thymoglobulin Compared with Alemtuzumab
*Purpose: The purpose of this study is to compare the outcomes of simultaneous pancreas and kidney transplant (SPK) recipients after two T-cell depleting induction agents:…2019 American Transplant Congress
Alemtuzumab Induction in Living Donor Renal Transplantation
The Ohio State University Wexner Medical center, Columbus, OH
*Purpose: About 15% of kidney transplant (KT) recipients receive alemtuzumab (ALM) for induction. The aim of this study was to review outcomes in living donor…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 31
- Next Page »